Abstracts tagged "rheumatoid arthritis"

Abstract Number: LB23 • ACR Convergence 2025
A Phase 1 Study of Autologous CAR-Treg Cells in Refractory Rheumatoid Arthritis: Interim Report of Safety and Efficacy
Minna Kohler¹, Sally Arai², Fawad Aslam³, Gregory Challener⁴, Matthew Frigault⁴, Melissa Griffith⁵, Tamiko Katsumoto⁶, Elena Massarotti⁷, Larry Moreland⁸, Allison Rosenthal⁹, Jeffrey Sparks⁷, Janeth Yinh⁴, Sarah Baxter¹⁰, Ari Bitton¹¹, Jason Dubovsky¹², Victor Yuan¹³, Mindy Jensen¹⁴, Andrew Clauw¹⁵, Gabrielle Furman⁴, Rita Gyurko⁷, Megan Hall⁹, Anna McIntyre⁴, Jennifer Seifert¹⁶, Emma Stainton², Michelle Blake¹⁰, Sabrina Fox-Bosetti¹³, Herve Lebrec¹³, Amanda Pace¹⁰, Yuanyuan Xiao¹⁷, Mei-Lun Wang¹⁸, Joe Arron¹³ and Jeffrey Bluestone¹⁹, ¹Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, ²Stanford, Palo Alto, California, ³Mayo Clinic, Arizona, Scottsdale, Arizona, ⁴Massachusetts General Hospital, Boston, Massachusetts, ⁵University of Colorado Anschutz Medical Campus, Aurora, Colorado, ⁶Stanford University, Millbrae, California, ⁷Brigham and Women's Hospital, Boston, Massachusetts, ⁸University of Colorado, Denver, Colorado, ⁹Mayo Clinic, Phoenix, Arizona, ¹⁰Sonoma Biotherapeutics, Seattle, Washington, ¹¹Sonoma Biotherapeutics, San Diego, California, ¹²Sonoma Biotherapeutics, Thousand Oaks, California, ¹³Sonoma Biotherapeutics, South San Francisco, California, ¹⁴Sonoma Bio, Seattle, Washington, ¹⁵University of Colorado, Aurora, Colorado, ¹⁶University of Colorado and Oklahoma Medical Research Foundation, Aurora, Colorado, ¹⁷Sonoma Biotherapeutics, Los Altos, California, ¹⁸Sonoma Biotherapeutics, San Francisco, California, ¹⁹Sonoma Biotherapeutics Inc, South San Francisco, California
Background/Purpose: Regulatory T cells (Tregs) modulate inflammation, maintain self-tolerance, promote tissue repair, and hold promise as a versatile therapeutic. Autologous polyclonal Tregs have a favorable…
Abstract Number: LB05 • ACR Convergence 2025
ER Stress-Induced ATP2A3 Drives Rheumatoid Arthritis via Activation of STING Signaling
yujie cai, Nanfang hospital, Guangzhou, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by persistent synovial inflammation and joint bone destruction. Endoplasmic reticulum (ER) stress plays an important role…
Abstract Number: LB15 • ACR Convergence 2025
Dietary Fiber Supplementation Enhances Methotrexate Response and Restores Th17/Treg Balance in Rheumatoid Arthritis: Results from the Superfibre Randomized Trial
Claire Immediato Daien¹, Jean-Pierre Hellier², Zübeyir Salis³, Gaël Mouterde⁴, Jacques Morel⁵, Laurence Macia⁶ and Rachel audo⁴, ¹CHU and Univesrity of Montpellier, Montpellier, France, ²CHU Montpellier, Arles, France, ³University of Montpellier, Montpellier, France, ⁴CHU Montpellier, Montpellier, France, ⁵CHU and University of Montpellier, Montpellier, France, ⁶Sydney University, Brisbane, Australia
Background/Purpose: Gut dysbiosis and Th17/Treg imbalance contribute to rheumatoid arthritis (RA). Additionally, methotrexate (MTX) efficacy depends on gut microbiota composition, especially on the presence of B.…
Abstract Number: LB19 • ACR Convergence 2025
Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial
Jonathan Graf¹, Amy Archer², Sergiy Kovalenko³, Katarzyna Kolossa⁴, John Serpa⁵, Tamta Kobakhidze⁶, Daniela Cepoi⁷, Andrea Everding⁸, Costantino Pitzalis⁹, Catherine Aversa², Martin Dahl², May Hafez², Paul Lizzul², Priya Raina², Bruce Randazzo², Yangsu Ren², Khalil Saikali², Cailin Sibley¹⁰, Gerd Burmester¹¹, Jacques-eric GOTTENBERG¹², Iain McInnes¹³, Eduardo Mysler¹⁴, Lee Simon¹⁵, Josef Smolen¹⁶, Jeffrey Sparks¹⁷, Ronald van Vollenhoven¹⁸, Michael Weinblatt¹⁹ and Paul Emery²⁰, ¹UCSF, San Francisco, California, ²AnaptysBio Inc, San Diego, California, ³Arensia Exploratory Medicine, Kyiv, Ukraine, ⁴MICS Centrum Medyczne, Bydgoszcz, Poland, ⁵Allied Biomedical Research Institute, Miami, Florida, ⁶Research Institute of Clinical Medicine Todua Clinic, Tbilisa, Georgia, ⁷Nicolae Testemitanu State University of Medicine & Pharmacy, Chisinau, Moldova, ⁸MVZ Rheumatologie & Autoimmunmedzin Hamburg GmbH, Hamburg, Germany, ⁹QMUL, Bromley Kent, United Kingdom, ¹⁰AnaptysBio Inc, San Diego, ¹¹Charité - Universitétsmedizin Berlin, Berlin, Germany, ¹²Hautepierre Hospital, STRASBOURG, France, ¹³University of Glasgow, Glasgow, United Kingdom, ¹⁴OMI, Buenos Aires, Argentina, ¹⁵SDG LLC, West Newton, Massachusetts, ¹⁶Medical University of Vienna, Vienna, Austria, ¹⁷Brigham and Women's Hospital, Boston, Massachusetts, ¹⁸Amsterdam UMC, Amsterdam, Netherlands, ¹⁹Brigham and Women's Hospital/ Harvard Medical School, Waban, Massachusetts, ²⁰University of Leeds, Leeds, United Kingdom
Background/Purpose: Over 50% of RA patients require multiple b/tsDMARD classes due to inadequate or lost response. Rosnilimab, an investigational monoclonal antibody that selectively targets and…
Abstract Number: 0022 • ACR Convergence 2025
Genome-wide association study identifies novel genetic risk factors for rheumatoid arthritis-associated interstitial lung disease
Austin Wheeler¹, Thomas Riley², Riku Takei³, Joshua Baker², Yangyuna Yang¹, Punyasha Roul⁴, Katherine Wysham⁵, Grant Cannon⁶, Gary Kunkel⁷, Gail Kerr⁸, Dana Ascherman⁹, Paul Monach¹⁰, Andreas Reimold¹¹, Jill Poole¹, Ted Mikuls¹, Tony Merriman¹² and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴UNMC, Omaha, NE, ⁵VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰VA Boston Healthcare System, Boston, MA, ¹¹Dallas VA Medical Center, Dallas, TX, ¹²University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Interstitial lung disease (ILD) is clinically present in ~10% of individuals with RA. There is recognized overlap between RA-ILD and idiopathic pulmonary fibrosis (IPF)…
Abstract Number: 0067 • ACR Convergence 2025
Identification of Neutrophil Extracellular Traps in Explanted Human Lungs with Rheumatoid Arthritis-related Interstitial Lung Disease
Amara Seng¹, Kensuke Suga², Diana Tran³, Anvita Singaraju⁴, Tanyalak Parimon⁵, Youn Jung Choi⁶, Justyna Fert-Bober⁷, Jon Giles⁸, Peter Chen⁵ and Nunzio Bottini⁹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Beverly Hills, CA, ³Cedars Sinai Medical Center, La Cañada Flintridge, CA, ⁴Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los Angeles, ⁵Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Cedars Sinai Medical Center, Los Angeles, CA, ⁹Cedars Sinai Medical Center, Beverly Hills, CA
Background/Purpose: Symptomatic rheumatoid arthritis-related interstitial lung disease (RA-ILD) is prevalent in about 10% of patients with RA and confers a higher mortality compared with RA…
Abstract Number: 0085 • ACR Convergence 2025
Single Cell RNA-seq Revealed Immune/epithelial Cell Abnormalities Underlying the Pathogenesis of Rheumatoid Arthritis-related Interstitial Lung Disease
Kensuke Suga¹, Amara Seng², Changfu Yao³, Tanyalak Parimon³, Youn Jung Choi², Justyna Fert-Bober⁴, Barry Stripp³, Jon Giles⁵, Peter Chen³ and Nunzio Bottini⁶, ¹Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Beverly Hills, CA, ²Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ³Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Cedars Sinai Medical Center, Los Angeles, CA, ⁶Cedars Sinai Medical Center, Beverly Hills, CA
Background/Purpose: Interstitial lung disease (ILD) is one of the extra-articular manifestations of rheumatoid arthritis (RA) characterized by inflammation and/or fibrosis. Clinically relevant RA-ILD occurs in…
Abstract Number: 0166 • ACR Convergence 2025
Effect of Air Pollution on Prevalence and Disease Activity of Rheumatoid Arthritis in the German Middle-aged Population from the NAKO Baseline Examination
Tim Filla¹, Gamal Chehab¹, Jutta Richter², Jörg Distler³ and Oliver Sander¹, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ²Clinic for Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, Düsseldorf, Germany, ³University Hospital Duesseldorf and HHU, Duesseldorf, Germany
Background/Purpose: Environmental influences affect the human body throughout life, from conception to old age. The influence of air pollution and fine dust particles on systemic…
Abstract Number: 0222 • ACR Convergence 2025
Evaluating the Barriers and Facilitators for Collecting and Documenting Rheumatoid Arthritis Disease Activity Measures Using a Rheumatology Provider Survey
Isaac Smith¹, Linda Tovar², Michael Battistone², Andrea Barker³, Bryant England⁴, Ankoor Shah⁵, Joshua Baker⁶, Katherine Wysham⁷, Beth Wallace⁸, Ted Mikuls⁴, Deanna Lazaro⁹, Pascale Schwab¹⁰, Paul Monach¹¹, Gail Kerr¹², Andreas Reimold¹³, Gary Kunkel², Liron Caplan¹⁴, John Richards¹⁵, Aleksander Lenert¹⁶, Andrew Jones¹⁷, Maria I. ("Maio") Danila¹⁸, Brian Sauer¹⁹, Jorge Rojas²⁰ and Grant Cannon²¹, ¹Duke University Hospital, Durham, NC, ²Salt Lake City VA, Salt Lake City, UT, ³Salt Lake City VA, Cottonwood Heights, UT, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Duke University, Durham, NC, ⁶University of Pennsylvania, Philadelphia, PA, ⁷VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹VA New York Harbor Healthcare System, Brooklyn, NY, ¹⁰Oregon Health & Science University, Portland, OR, ¹¹VA Boston Healthcare System, Boston, MA, ¹²Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹³Dallas VA Medical Center, Dallas, TX, ¹⁴University of Colorado, Denver, CO, ¹⁵Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹⁶Iowa Carver College of Medicine, Iowa City, IA, ¹⁷VA Saint Louis and Washington University, Saint Louis, ¹⁸University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ¹⁹Salt Lake City VA/University of Utah, Salt Lake City, UT, ²⁰VA Puget Sound Health Care System, Seattle, WA, ²¹University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Collection of disease activity measures (DAMs) is a key component of high-quality care for rheumatoid arthritis (RA) patients. This study surveyed rheumatology providers at…
Abstract Number: 0431 • ACR Convergence 2025
Calprotectin Serum levels: a potential neutrophil activation biomarker to monitor treatment response in Rheumatoid Arthritis
Sangeeta Kumari¹, Eric meldrum¹, Josephine Stein¹, Tirza Bruurmijn¹, Robin de Jong², Katerina Pardali¹, Maarten Kraan¹, Renato Chirivi¹, Rogier Thurlings³ and Michael Nurmohamed², ¹Citryll BV, Oss, Netherlands, ²Reade, Amsterdam, Netherlands, ³Radboudumc, Nijmegen, Netherlands
Background/Purpose: Calprotectin is a protein highly expressed in myeloid cells and its elevated presence in blood, and the GI tract is associated with immune mediated…
Abstract Number: 0448 • ACR Convergence 2025
Implementing Artificial Intelligence to Identify Rheumatoid Arthritis Flares Using Electronic Medical Records Processed with Privacy-Preserving Large Language Models: A Pilot Study
Ioannis Koulas¹, Nikolaos Tsaftaridis², Marios Gkionis³, Giancarlo Paternoster⁴, Sunit Jariwala⁵ and Konstantinos Loupasakis⁶, ¹Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, ²The Feinstein Institutes for Medical Research, Manhasset, ³NTNU, Department of Engineering Cybernetics, Trondheim, Norway, ⁴Albert Einstein College of Medicine, Bronx, NY, ⁵Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ⁶Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Although Large Language Models (LLMs) have been successfully used in the analysis of data from Electronic Health Records (EHRs), their implementation in the field…
Abstract Number: 0465 • ACR Convergence 2025
Reproductive Factors and Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease or Bronchiectasis in Women
Suchita Nety¹, Xiaosong Wang², Misti Paudel³, Ying Qi⁴, Qianru Zhang¹, Nancy Shadick⁵, Michael Weinblatt⁶, Liya Sisay Getachew⁷, Gregory McDermott⁸ and Jeffrey Sparks⁷, ¹Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Natick, MA, ³Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁴Brigham and Women’s Hospital, Boston, ⁵Brigham & Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Brigham and Women's Hospital, Brookline, MA
Background/Purpose: RA-associated lung diseases (RA-LD) such as RA-associated interstitial lung disease (RA-ILD) and RA-associated bronchiectasis (RA-BR) are more common in men, but risk rises with…
Abstract Number: 0481 • ACR Convergence 2025
Intracellular Methotrexate Polyglutamate Profiles Do Not Correlate with Early Clinical Response in Treatment-Naïve Rheumatoid Arthritis: A Prospective Study
Chandrashekara MN¹, AASTHA KHULLAR², Bidyalaxmi Leishangthem³, Shankar Naidu⁴, Varun Dhir⁵ and Sanjay Jain⁴, ¹PGIMER, Chandigarh, Chandigarh, India, ²Postgraduate Institute of Medical Education and Research, CHANDIGARH, Chandigarh, India, ³PGIMER, Chandigarh, India, Chandigarh, Chandigarh, India, ⁴Post graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, Chandigarh, India, ⁵PGIMER, CHD, INDIA, CHANDIGARH, Chandigarh, India
Background/Purpose: Methotrexate (MTX) polyglutamates (MTX-PGs), the intracellular active forms of MTX, are hypothesized to reflect cumulative exposure and potentially predict therapeutic efficacy in rheumatoid arthritis…
Abstract Number: 0499 • ACR Convergence 2025
Olokizumab Improves Patient-Reported Outcomes in Rheumatoid Arthritis MTX-IR and TNF-IR Patients up to 106 Weeks (Results from Clinical Phase III Program)
Roy Fleischmann¹, Eugen feist² and Josef Smolen³, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ³Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria
Background/Purpose: Olokizumab (OKZ), an interleukin-6 inhibitor approved in several countries for managing rheumatoid arthritis (RA), was evaluated in previous phase III RCTs, demonstrating changes in…
Abstract Number: 0800 • ACR Convergence 2025
Microbiota-Derived Indole Promotes Collagen-Induced Arthritis Type-17 Immunity through Intestinal Dendritic Cell Cytokine Production
Jing Jing Li¹, Sucai Liu², Brenda Seymour³, Brendan Allen², Le Yiphyo², Cassandra Levens¹ and Kristine Kuhn⁴, ¹Rheumatology, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO, ³University of Colorado School of Medicine, Denver, CO, ⁴²⁰²² - ²⁰²³ / Adult/ University of Colorado, Aurora, CO
Background/Purpose: One of the most substantial impacts of microbe-host interactions at the intestinal mucosa is the development of type 17 immunity. A Th17 signature has…

1
2
3
…
219
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].